Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022 ...Middle East

PR Newswire - News
Data presented highlight strong immune responses (proof-of-concept) correlating to clinical benefit in patients with adrenocortical carcinoma (ACC) EO2401 plus nivolumab shows efficacy in a subpopulation of patients with ACC, which was defined retrospectively using a set of clinical...

Hence then, the article about enterome presents proof of concept immune response data and first clinical data from phase 1 2 trial with eo2401 a first in class oncomimics therapeutic cancer vaccine for adrenocortical carcinoma at asco 2022 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022 )

Apple Storegoogle play

Last updated :

Also on site :